In 2015, NCCN introduced the NCCN evidence blocks which is a tool that allowed for clinicians and patients to have a conversation about what is important to a patient’s individual value system, said Lyn Fitzgerald, senior vice president of US & Global Development at NCCN.
Transcript:
How is NCCN working to define and assess “value” in cancer care?
So, the panel today I talked about the NCCN categories of preference. So, in 2015, NCCN introduced the NCCN evidence blocks which is a tool that allowed for clinicians and patients to have a conversation about what is important to a patient’s individual value system. We’d consider the efficacy of a therapy, safety, quality of the evidence, consistency of the evidence, and affordability.
The categories of preference are another step, it’s another tool to help clinicians with understanding what is optimal care. We believe that value truly is defined by an individual patient’s need and so the categories of preference allow for our panel members to signal to clinicians of all the recommendations in the NCCN guidelines, which are the preferred.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More